Dr Melissa Ooi

Consultant, Department of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS)

 

Dr. Melissa Ooi graduated from Royal College of Surgeons in Ireland. She underwent medical and haematology training in Ireland where she obtained her postgraduate qualification. During her specialty training, she was awarded a research fellowship in the Jerome Lipper Multiple Myeloma Center in Dana Farber Cancer Institute, Harvard Medical School, Boston, USA. She worked under Professor Kenneth Anderson and Dr. Constantine Mitsiades in Dana Farber and with Dr. Peter O’Gorman, Professor Martin Clynes and Dr. Robert O’Connor in the National Institute of Cellular Biotechnology in Dublin City University. This collaborative research resulted in a number of peer-reviewed journal publications and presentations in international meetings. Dr. Ooi was awarded her PhD from Dublin City University in 2011. She then went on to complete her haematology specialist training and was awarded her CSCST in 2013. Her interests include treatment of patients with plasma cell dyscrasias, acute leukemia and myelodysplastic/myeloproliferative neoplasms.

 

Education and Fellowships

MB BCh, BAO, MRCP(I), FRCPath, PhD

 

Specialty Interests

  • Plasma cell dyscrasias
  • Acute leukaemia
  • Myelodysplasia

 

Awards and Honours

  • Oral presentation for William Stokes Award (2011)
  • SPORE Myeloma Career Development Award (2009)
  • International Research Fellowship (Ireland) (2007)

 

Selected Publications

  1. Ong SY, de Mel S, Chen YX, Ooi MG, Surendran S, Lin A, Koh LP, Linn YC, Ho AY, Hwang WY, Phipps C, Loh SM, Goh YT, Tan D, Chng WJ, Gopalakrishnan SK. Early relapse post autologous transplant is a stronger predictor of survival compared with pretreatment patient factors in the novel agent era: analysis of the Singapore Multiple Myeloma Working Group. Bone marrow Transplant 2016 Mar 14 [Epub ahead of print]. (IF – 3.57) 
  2. Ooi MG, de Mel S, Chng WJ. Risk Stratification in Multiple Myeloma. Curr Hematol Malig Rep. 2016 Apr;11(2):137-47 Epub Feb 16. (IF – 2.286)
  3. Ooi MG, O’Connor R, Meiller J, Jakubikova J ,Klippel S, Delmore J, Richardson P, Anderson K, Clynes M, Mitsiades CS, O’Gorman P.  The Interaction of Bortezomib with Multidrug Transporters: Implications for Therapeutic Applications in Advanced Multiple Myeloma and Other Neoplasias. Cancer Chemother Pharmacol. 2013 May;71(5):1357-68. Epub 2013 Apr 16.(IF – 2.8) 
  4. Klippel S, Jakubikova J, Delmore J, Ooi M, McMillin D, Kastritis E, Laubach J, Richardson PG, Anderson KC,  Mitsiades CS. Methyljasmonate displays in vitro and in vivo activity against multiple myeloma cells.Br J Haematol. 2012 Nov;159(3):340-51. Epub 2012 Sep 13. (IF – 4.942)
  5. Jakubikova J, Cervi D, Ooi M, Kim K, Nahar S, Klippel S, Cholujova D, Leiba M, Daley JF, Delmore J, Negri J, Blotta S, McMillin D, Hideshima T, Richardson P, Sedlak J, Anderson K, Mitsiades CS.Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and PEITC in multiple myeloma. Haematologica. 2011Aug;96(8):1170-9. Epub 2011 Jun 28.(IF- 5.9)
  6. McMillin DW, Delmore J, Negri J, Ooi M, Klippel S, Miduturu CV, Gray NS, Richardson PG, Anderson KC, Kung AL, Mitsiades CS. Microenvironmental influence on pre-clinical activity of polo-like kinase inhibition in multiple myeloma: implications for clinical translation. PLoS One. 2011;6(7):e20226. Epub 2011 Jul 7. (IF – 3.73)
  7. Jakubikova J, Adamia S, Kost-Alimova M, Klippel S, Cervi D, Daley JF, Cholujova D, Kong SY, Leiba M, Blotta S, Ooi M, Delmore J, Laubach J, Richardson PG, Sedlak J, Anderson KC, Mitsiades CS. Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. Blood. 2011 Apr 28;117(17):4409-19. Epub 2011 Feb 14.(IF – 9.898)
  8. McMillin DW, Delmore J, Negri J, Buon L, Jacobs HM, Laubach J, Jakubikova J, Ooi M, Hayden P, Schlossman R, Munshi NC, Lengauer C, Richardson PG, Anderson KC, Mitsiades CS. Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications. Br J Haematol. 2011 Feb;152(4):420-32. doi: 10.1111/j.1365-2141.2010.08427.x. Epub 2011 Jan 11. (IF – 4.942)
  9. Ooi MG, Hayden PJ, Kotoula V, McMillin DW, Charalambous E, Daskalaki E, Raje NS, Munshi NC, Chauhan D, Hideshima T, Buon L, Clynes M, O'Gorman P, Richardson PG, Mitsiades CS, Anderson KC, Mitsiades N. Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib. Clin Cancer Res. 2009 Dec 1;15(23):7153-60. Epub 2009 Nov 24.(IF – 6.747)
  10. McMillin DW, Ooi M, Delmore J, Negri J, Hayden P, Mitsiades N, Jakubikova J, Maira SM, Garcia-Echeverria C, Schlossman R, Munshi NC, Richardson PG, Anderson KC, Mitsiades CS. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. Cancer Res. 2009 Jul 15;69(14):5835-42. Epub 2009 Jul 7. (IF – 7.543)

 

 

 

Updated as of 16 June 2017